Oncogenic ARAF mutation in a metastatic lung adenocarcinoma from a patient exhibiting sustained sorafenib response.

被引：0
|
作者：
Greulich, Heidi E. [1 ]
Imielinski, Marcin [1 ]
Kaplan, Bethany [1 ]
Araujo, Luiz [2 ]
Amann, Joseph [2 ]
Horn, Leora [3 ]
Villalona, Miguel [2 ]
Meyerson, Matthew [1 ]
Carbone, David [2 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Ohio State Univ, Columbus, OH 43210 USA
[3] Vanderbilt Univ, Nashville, TN 37235 USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2013年 / 12卷 / 11期
关键词：
D O I：
10.1158/1535-7163.TARG-13-C139
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C139
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Near complete response to ceritinib in a pediatric patient with metastatic ALK-rearranged lung adenocarcinoma
    Liu, Zuhui
    Liu, Maolin
    Hou, Xue
    LUNG CANCER, 2023, 176 : 140 - 143
  • [22] Response to savolitinib in a patient with lung adenocarcinoma harboring a novel MET exon 14 skipping mutation
    Liu, Zhenkun
    Li, Pengfei
    Wu, Qiang
    Zhou, Qinghua
    ASIAN JOURNAL OF SURGERY, 2024, 47 (04) : 1851 - 1852
  • [23] Durable response to immunotherapy plus chemotherapy in a patient with untreated, brain-metastatic, EGFR exon 20 insertion mutation lung adenocarcinoma A case report
    Nong, Jingying
    Gu, Yanfei
    Yao, Shuyang
    Zhang, Yi
    MEDICINE, 2021, 100 (29) : E26650
  • [24] Major Therapeutic Response to T-DM1 in Metastatic Lung Adenocarcinoma with HER2 Mutation
    Berardi, G.
    Toffart, A. C.
    Pinsolle, J.
    Moro-Sibilot, D.
    Levra, M. Giaj
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1032 - S1032
  • [25] Dramatic response of acute disseminated intravascular coagulation to erlotinib in a patient with lung adenocarcinoma with activating EGFR mutation
    Kim, Jung Soo
    Ryu, Jeong-Seon
    Jeon, Sang Hoon
    Kim, Hyun-Jung
    Nam, Hae-Seong
    Cho, Jae Hwa
    Kwak, Seung Min
    Lee, Hong Lyeol
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2018, 46 (01) : 533 - 537
  • [26] Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation
    Takamori, Shinkichi
    Matsubara, Taichi
    Fujishita, Takatoshi
    Ito, Kensaku
    Toyozawa, Ryo
    Seto, Takashi
    Yamaguchi, Masafumi
    Okamoto, Tatsuro
    THORACIC CANCER, 2021, 12 (06) : 978 - 980
  • [27] Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation
    Rotow, Julia K.
    Woodard, Gavitt A.
    Urisman, Anatoly
    McCoach, Caroline E.
    Bivona, Trever G.
    Elicker, Brett M.
    Jablons, David M.
    Blakely, Collin M.
    CLINICAL LUNG CANCER, 2019, 20 (02) : E137 - E141
  • [28] Sustained response to standard dose osimertinib in a patient with plasma T790M-positive leptomeningeal metastases from primary lung adenocarcinoma
    Chan, Oscar Siu-Hong
    Leung, Warren Kam-Wing
    Yeung, Rebecca Mei-Wan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (06) : 428 - 430
  • [29] A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib
    Chen, Hua-fei
    Wang, Wen-xian
    Xu, Chun-wei
    Huang, Li-chao
    Li, Xiao-feng
    Lan, Gang
    Zhai, Zhan-qiang
    Zhu, You-cai
    Du, Kai-qi
    Lei, Lei
    Fang, Mei-yu
    LUNG CANCER, 2020, 142 : 59 - 62
  • [30] A novel SOS1-ALK fusion variant in a metastatic lung adenocarcinoma patient with remarkable response to crizotinib
    Xu, C.
    Wang, W.
    Lei, L.
    Chen, H.
    Huang, L.
    Li, X.
    Lan, G.
    Zhai, Z.
    Zhu, Y.
    Wang, J.
    Chen, G.
    VIRCHOWS ARCHIV, 2020, 477 : S335 - S335
12345